Thomas E. Shenk
Independent Director & Member of Scientific Advisory BoardDr. Thomas E. Shenk, also known as Tom, Ph.D., serves as an Independent Director at MeiraGTx Holdings plc (formerly known as MeiraGTx Limited) since June 2015. He is Co-Founder of IMMVIRA CO., Ltd and also serves as its Member of Scientific Advisory Board. He co-founded PMV Pharmaceutcals, Inc. in 2013. Dr. Shenk is the Founder of Novalon and Evrys Bio, LLC (formerly known as FORGE Life Science, LLC). He is a Scientific Founder of DNX, Inc., Cadus Pharmaceutical Corporation and Merlin Pharmaceutical Corporation. Dr. Shenk served as Director at MeiraGTx Holdings plc (formerly known as MeiraGTx Limited) since June 2015. He serves as Director of the American Philosophical Society. Dr. Shenk served as an Advisor of The Sage Group, Inc. Dr. Shenk serves as Editor-in-Chief at The Journal of Virology. He served as the President of American Society for Microbiology and Virology. He served as an Investigator of Howard Hughes Medical Institute from 1989 to 1999. He is a world-renowned expert in virology and gene therapy and has experience in the biopharmaceutical field. He serves as the Chairman of Scientific Advisory Board at Karo Bio USA, Inc. He has been a Director of Hepatitis B Foundation since February 29, 2012 and CV Therapeutics Inc. since December 16, 2004. He served as Chairman of the Board at MeiraGTx Holdings plc (formerly known as MeiraGTx Limited) and serves as Member of Scientific Advisory Board. He serves as a Director of Fox Chase Cancer Center, Evrys Bio, LLC (formerly known as FORGE Life Science, LLC), Origen Therapeutics, Inc., Cadus Pharmaceutical Corporation and Karo Bio USA Inc. He served as a Member of Scientific Advisory Board of PMV Pharmaceutcals, Inc. until 2024. He serves as a Trustee of Merck Company Foundation, The. He served as a Director of Merck & Co., Inc. from 2001 to February 8, 2012 and Cell Genesis. He served as a Director of Somatix Therapy Corp. in conjunction with Somatix's acquisition of Merlin Pharmaceutical Corporation (Merlin) since February 1995. He served as the Chairman of General Advisory Board at Signum Biosciences, Inc. He served as the Chairman of Department of Molecular Biology at Princeton University since 1996. He served as a Member of Scientific Advisory Board at Cell Genesys Inc., since 1997 and served as its Director since August 2001. He served as a Director of Gilead Palo Alto Inc. since December 16, 2012. He was the James A. Elkins Professor of Life Sciences in the Department of Molecular Biology at Princeton University from 1984 to 2021, when he became Professor of Life Sciences, Emeritus. Dr. Shenk had served as a Director of Kadmon Holdings, Inc. from 2014 to June 2018 and served as its member of Scientific Advisory Board since December 2013. He serves as a Member of the U.S. National Academy of Medicine, the Institute of Medicine, the American Academy of Arts and Sciences and the American Academy of Microbiology. He has done extensive work with adenovirus. He has published more than 225 scientific papers in various journals and has authored multiple patents in the area of transcriptional regulation, molecular oncology and virology. He was trained as a Postdoctoral Fellow in Molecular Biology at Nobel laureate Paul Berg at Stanford Medical Center, Stanford University. He has received numerous career honors and awards. He served as Director at Vical Incorporated., since December 18, 2015 until August 2019. Dr. Shenk has B.S. in Biology from the University of Detroit and Ph.D. in Microbiology from Rutgers University.
Positions
- Company NameMeiraGTx Holdings plcStock CodeMGTXPositionIndependent Director & Member of Scientific Advisory BoardColleagues
- AFAlexandria ForbesCEO, President & Director
- KRKeith Reginald HarrisIndependent Chairman of the Board
- RBRichard Brian GirouxCOO & CFO
- RKRobert K. ZeldinChief Medical Officer
- RJRobert J. WollinGeneral Counsel & Secretary
- SNStuart NaylorChief Scientific Officer of Ophthalmology
- GAGregory A. PetskoChairman of Scientific Advisory Board
- NSNicole SeligmanIndependent Director
